- Mike Connell appointed as VP, Commercial to lead global commercial activities
- Mr Connell has extensive experience in sales, marketing and strategy across the pharmaceutical, healthcare and FMCG industries
- Mr Connell has previously held senior roles with GlaxoSmithKline (GSK) and Medibank
- Mr Connell was responsible for launching GSK’s European Established Products business which delivered a significant share of the £3Bn in global sales during 2014
Brisbane, Australia, 11 January 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has appointed Mr Mike Connell as Vice President (VP), Commercial.
Mr Connell is a leading executive with extensive sales, marketing and strategy experience in pharmaceuticals, health insurance and fast-moving consumer goods (FMCG).
Mr Connell has over a decade of healthcare experience, including a longstanding position with GlaxoSmithKline (GSK). He joined GSK as an Australian-based sales and marketing manager and was shortly promoted to VP level roles across Europe.
During his time with GSK, Mr Connell launched and led GSK’s European Established Products business, which delivered a significant share of GSK’s Established Products segment sales, which totalled £3Bn during 2014.
Most recently, he was General Manager, Corporate Portfolio at Medibank. During this role, Mr Connell was responsible for corporate health partnerships.
As VP, Commercial for ResApp, Mr Connell will be responsible for the company’s global commercial activities. Mr Connell is based in Melbourne and holds a Bachelor of Business (Marketing/Economics) from Swinburne University. He will report directly to CEO and Managing Director Dr Tony Keating.
CEO and Managing Director Dr Tony Keating said: “We are very pleased to have attracted someone of Mike’s calibre to the ResApp team. He brings deep commercial leadership and a strong understanding of the healthcare and FMCG sectors, which will be pivotal as the company continues to target high growth markets and partnerships with industry leading companies.”
VP, Commercial Mr Mike Connell said: “I am excited to be joining ResApp, particularly at such an important time in the company’s growth trajectory. ResApp has an established and clinically proven suite of products, which will provide a number of potential growth pathways and corporate development opportunities. I look forward to working with Tony and the team to unlock shareholder value and significant benefits for our customers and patients over the coming months.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.